Advanced Respiratory Physiology and Pathophysiology: Lung Mechanics and Disease

Mechanical Aspects of Lung Function

• Structural Stability: Lungs are composed of delicate, bubble-like structures called alveoli. Despite their fragile nature, they are stable and resist collapse under most normal physiological conditions.

• Role of Surfactant: Alveoli are lined with surfactant, which reduces surface tension. This reduction in tension resists alveolar collapse and significantly eases the process of lung inflation.

• Lung Compliance: The lungs are highly compliant, meaning they can easily accommodate a standard tidal volume ($V_T$) of approximately $500\,mL$ with very small changes in distending pressure.

  • The distending pressure required for this volume is only about $3\,cm\,H_2O$, which is less than $1\,mm\,Hg$.

• Airway Resistance: Airways maintain very low resistance to airflow. During inspiration, air moves down a pressure gradient of less than $1\,cm\,H_2O$.

Pulmonary Function Tests (PFTs) and Lung Volumes

• Measurement Setting: Measurements of lung volumes and capacities are typically conducted in a specialized Pulmonary Function Test (PFT) laboratory.

• Volumes vs. Capacities:

  • Volumes: Discrete measurements that do not overlap.

  • Capacities: Calculated measurements that can overlap, as they are the sum of two or more lung volumes.

• Standard PFT Measures:

  • Residual Volume (RV): The amount of air remaining in the lungs after a maximal expiration. It cannot be measured via standard spirometry. Instead, it is measured using specialized tests such as plethysmography or helium dilution. The RV value is essential for calculating Functional Residual Capacity (FRC) and Total Lung Capacity (TLC).

  • Functional Residual Capacity (FRC): The volume of air remaining in the lungs after a normal, quiet expiration ($FRC = RV + ERV$).

  • Tidal Volume ($V_T$): The volume of air moved during a single normal, quiet breath.

  • Total Lung Capacity (TLC): The total volume of air in the lungs following a maximal inspiration ($TLC = VC + RV$).

  • Vital Capacity (VC): The total volume of air that can be moved during a complete expiration starting from TLC. It is also calculated as $VC = TLC - RV$.

• Pathological Changes: Lung pathologies alter these PFT results in highly characteristic ways, allowing for clinical differentiation between disease states.

Functional Residual Capacity (FRC) and Thoracic Equilibrium

• Equilibrium Position: FRC represents the equilibrium point where the elastic forces of the respiratory system are balanced. The lungs possess an inherent tendency to collapse inward, while the chest wall possesses a tendency to expand outward.

• Force Balance: At FRC, these two opposing forces are equal in magnitude and opposite in direction. Because they balance each other, no additional muscular work is required to keep the lungs open at this volume.

• Impact of Alterations: Changes in either the properties of the lung tissue or the chest wall can shift the FRC:

  • Decreased FRC: Seen in restrictive diseases such as pulmonary fibrosis. This often results in a narrow chest appearance.

  • Increased FRC: Seen in obstructive diseases such as emphysema and Chronic Obstructive Pulmonary Disease (COPD). This typically results in a large, barrel-shaped chest due to the chest wall expanding further to meet the reduced inward recoil of the lungs.

Respiratory System Pressures

• Atmospheric Pressure ($P_{atm}$): The airways are in contact with the atmosphere; for measurement purposes, $P_{atm}$ is defined as zero.

• Alveolar Pressure ($P_A$): The pressure within the airways and alveoli. It returns to zero (atmospheric) at the exact moments of end-inspiration and end-expiration.

• Pleural Pressure ($P_{pl}$): The pressure within the pleural space is normally negative, which acts to pull the lungs open and keep them inflated.

• Transpulmonary Pressure ($P_T$ or Distending Pressure): Defined as the pressure difference across the lung wall, calculated as the pressure inside minus the pressure outside ($P_A - P_{pl}$). Under resting conditions, this is approximately $5\,cm\,H_2O$.

• Dynamics During Inspiration:

  • Inspiration is initiated by the descent of the diaphragm and the expansion of the chest wall.

  • Throughout the process of inspiration, $P_T$ remains positive.

  • By the end of inspiration, the distending pressure increases from the resting $5\,cm\,H_2O$ to about $8\,cm\,H_2O$.

• Pneumothorax: This condition occurs when the pleural space is breached, allowing $P_{pl}$ to equilibrate with $P_{atm}$. This loss of the pressure gradient removes the force holding the lung open, leading to lung collapse.

Compliance and Elastance

• Compliance: This is the ease with which the lungs expand. Normal lungs require only a few $cm\,H_2O$ to reach tidal volume.

  • High Compliance: Seen in emphysema. The lungs take less pressure and effort to distend but lose their ability to recoil.

  • Low Compliance: Seen in lung fibrosis. Greater pressure is required to distend the lungs, often leading to a decreased tidal volume.

• Elastance (Elastic Recoil): Elastance is the mathematical inverse of compliance ($Elastance = \frac{1}{Compliance}$). It reflects the ability of the lung to spring back after being stretched.

  • Factors: Recoil is largely due to elastin fibers within the walls of the alveoli and bronchioles.

  • High Compliance/Low Elastance (Emphysema): Results in difficulty with passive expiration and lung emptying.

  • Low Compliance/High Elastance (Fibrosis): Expiration is often normal or even accelerated because the stiff lungs recoil forcefully.

Lung Protection Mechanisms and Pathophysiology

• Vulnerabilities: The delicate lung tissues are susceptible to damage from:

  • Exogenous sources: Inhaled pollutants, particulate matter, and compounds in cigarette smoke.

  • Endogenous sources: Reactive oxygen species (ROS) and proteases released by macrophages and neutrophils in response to foreign substances.

• Protective Systems:

  • Mucociliary Clearance: The "mucus escalator" that traps and removes particles.

  • Immunoglobulin A (IgA): Provides immune defense at the mucosal surface.

  • Alveolar Macrophages: Phagocytose invaders and utilize proteases and ROS to kill them.

  • Alpha-1 Antiprotease (Alpha-1 Antitrypsin/AAT): A protein produced by the liver. Its primary role is to inhibit leukocyte proteases, preventing them from damaging the body's own lung tissues.

Emphysema Pathophysiology

• The Imbalance: Emphysema results from an imbalance between lung-damaging forces and protective mechanisms.

• Risk Factors:

  • Smoking: Increases risk by introducing damaging substances, activating leukocytes, and inhibiting protective mechanisms.

  • Genetic Susceptibility: While most smokers do not develop emphysema, no single causative gene is identified for most.

  • Alpha-1 Antitrypsin (AAT) Deficiency: A specific genetic disorder. Individuals homozygous for the abnormal AAT gene are at extremely high risk, particularly if they smoke.

• Structural Changes: The disease causes the breakdown of alveolar walls, small airways, and surrounding connective tissue.

• Functional Consequences:

  • Compliance increases and elastance decreases.

  • Airspaces enlarge and air trapping occurs, leading to the formation of blebs and bullae (air pockets useless for gas exchange).

  • Loss of elasticity compromises expiration.

  • PFT Changes: RV, FRC, and TLC all increase due to air trapping; however, Vital Capacity (VC) decreases.

Restrictive Lung Diseases

• Definiton: Infiltrative processes that cause the accumulation of connective tissue and fluid, making lungs stiff (low compliance) and difficult to inflate.

• Chronic Infiltrative Conditions:

  • Idiopathic pulmonary fibrosis.

  • Occupational pneumoconiosis (exposure to asbestos, silica, or mining dust).

  • Sarcoidosis.

  • Scleroderma.

  • Systemic lupus erythematosus (SLE).

• Acute Infiltrative Conditions:

  • Pulmonary edema.

  • Severe generalized pneumonia.

  • Acute/Adult Respiratory Distress Syndrome (ARDS): Damage to alveolar integrity and death of Type 2 Alveolar Epithelial Cells (AEC) leads to reduced surfactant, higher surface tension, and widespread alveolar collapse.

• Functional Impact:

  • Thickening of the alveolar extracellular matrix and collagen accumulation.

  • PFT Changes: Reduction in RV, FRC, VC, and TLC.

  • Gas Exchange: Diffusion is limited due to the thickened physical barrier.

Airway Resistance and Forced Maneuvers

• Airway Architecture: The lungs consist of many generations of branching airways. As the generation number increases (moving deeper into the lung), the total cross-sectional area increases and the summed resistance decreases.

• Primary Resistance Site: Most airway resistance occurs in generations 2 through 7. This is heavily influenced by the tone of bronchial smooth muscle.

• Volume Dependence: Airway resistance is lowest at high lung volumes (near TLC) because airways are pulled to their maximum diameter.

• Forced Expiratory (FE) Maneuvers:

  • A test where the subject takes a maximal inspiration and blows air out as hard and fast as possible.

  • Muscles involved: Internal intercostals (pulling ribs down and in) and abdominal muscles (forcing abdominal contents against the diaphragm to shorten the thorax).

  • This maneuver creates positive pleural pressure to drive air out.

Flow-Volume Loop Dynamics

• Peak Flow: The initial maximum flow rate achieved during forced expiration.

• $FEV_1$: Forced Expiratory Volume in the first second. In healthy individuals, this is usually about $80\%$ of the Forced Vital Capacity (FVC).

• Airway Collapse: During forced expiration, as lung volume decreases, airflow slows. This happens because the positive pleural pressure eventually exceeds the pressure inside the airways (transpulmonary pressure becomes negative), causing the small airways to compress and collapse.

• Obstructive Disease Loop Characteristics:

  • FEV1/FVC Ratio: Significantly reduced (below normal).

  • Peak Flow: Greatly reduced (often less than half of normal).

  • Loop Shape: The expiratory curve becomes "scooped out" due to premature airway closure.

  • Shifting: The RV and TLC points are shifted to the left on the x-axis due to air trapping.

Cellular Regulation of Airway Tone

• Bronchoconstriction: Mediated by Acetylcholine (ACh) and other bronchoconstrictors.

  • Mechanism: They act through the phospholipase C (PLC) system to increase intracellular calcium ($Ca^{2+}$), which triggers bronchial smooth muscle contraction.

• Bronchodilation: Mediated by Epinephrine (Epi) and other bronchodilators.

  • Mechanism: They act through the cyclic AMP (cAMP) system to inhibit bronchial smooth muscle contraction.

Asthma: Pathogenesis and Progression

• Onset: Frequently begins in childhood.

• Hypersensitivity: Driven by a Type 1 hypersensitivity reaction.

  • Allergen exposure sensitizes T helper lymphocytes (specifically Th2-type).

  • Cytokine Cascade: Elevation of Interleukin-4 ($IL-4$), $IL-5$, and $IL-13$ promote B cell class switching.

  • Antibody Shift: The immune response shifts from IgG to IgE.

  • Mast Cell Involvement: IgE binds to mast cells. Upon re-exposure to the allergen, mast cells degranulate, releasing histamine and producing leukotrienes.

• Phases:

  • Acute Attack: Primarily mediated by histamine and leukotrienes (reversible obstruction).

  • Late Response: Characterized by the infiltration of eosinophils and other inflammatory cells.

• Adulthood and Management: Triggers can expand to include aspirin, exercise, cold air, and infections. Chronic asthma leads to smooth muscle hypertrophy and mucus hypersecretion. Management focuses on suppressing inflammation (inhaled corticosteroids, leukotriene antagonists) and bronchodilation.

Chronic Obstructive Pulmonary Disease (COPD)

• Nature: Characterized by persistent, non-reversible airway obstruction.

• Chronic Bronchitis: The most common form of COPD, typically caused by cigarette smoking.

• Signs/Symptoms:

  • Persistent productive cough.

  • Obstructive PFT findings (notably a decreased $FEV_1/FVC$ ratio).

  • Physical signs: Increased anterior-posterior (A-P) chest dimension (barrel chest), cyanosis, and pursed-lip breathing.

• Pathology: Includes leukocyte infiltration, mucosal edema, smooth muscle hypertrophy, and hypersecretion of mucus.

Obstructive Sleep Apnea

• Epidemiology: Incidence is rising alongside increasing rates of obesity.

• Mechanism: Reversible obstruction of the upper airway during sleep, most frequent when in the supine position.

• Diagnosis: Sleep studies track the number of apneic (no breathing) and hypopneic (reduced breathing) episodes per hour.

• Consequences: Partial arousals throughout the night lead to disrupted sleep and excessive daytime sleepiness. If untreated, it is linked to a significantly increased cardiovascular risk profile.

• Management: Primarily treated with Continuous Positive Airway Pressure (CPAP).